Telix Pharmaceuticals' quarterly revenue exceeds AU$200M
Telix Pharmaceuticals (ASX:TLX) reveals its quarterly revenues while also reaffirming its full-year 2024 revenue guidance.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
MDG | Ann: Removal from Official List - Close of trade today | 06/02/17 | 0 | 1.0K | |||
|
|||||||
MDG | Ann: Suspension from Official Quotation - Close of trade today | 30/01/17 | 0 | 836 | |||
|
|||||||
MDG | Ann: Appendix 4C - quarterly | 27/01/17 | 0 | 721 | |||
|
|||||||
MDG | Ann: Response to ASX Appendix 3Y Query | 03/01/17 | 0 | 743 | |||
|
|||||||
MDG | Ann: Change of Director's Interest Notice | 23/12/16 | 0 | 591 | |||
|
|||||||
MDG | Ann: Change in substantial holding | 23/12/16 | 0 | 595 | |||
|
|||||||
MDG | Ann: Results of Meeting | 14/12/16 | 0 | 507 | |||
|
|||||||
MDG | Ann: Half Year Accounts | 09/12/16 | 1 | 985 | |||
|
See All Discussions